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INTRODUCTION 
Nanotechnology possesses enormous potential to produce 
products, with novel properties, in various domains, whose 
importance is expected to get enhanced, in near future. 
Novel materials and devices resulting from said 
technology have broad introduction potentiality in all 
domain including biotechnology, food, and pharmaceutical 
sector. In pharmaceutical field, introduction of 
nanotechnology is achieving in devising 
nanotherapeuticsand nanodevices. Semi-biological 
nanodevicesare multifunctionaloffering versatile 
therapeutic services and demonstrating unitary 
biochemical activities. While amalgamation of imaging 
and therapeutic function in a single nanodevice can 
provide prognostic information concurrent with therapeutic 
intervention
1
. 
Presently, pharmaceuticals containing nanotherapeuticsand 
nanodevicesare under extensive study for improving 
performance 
1
. Ongoing attempt is to present them as 
disinfectants; biosensor or bio-tracer based diagnostic 
agent for detecting toxins, pathogens, volatile compounds, 
and organic components of body fluids; and for monitoring 
diseases
1
. Besides these they will revolutionise offering of 
device for site-specific controlled delivery of drug or drug 
targeting, and presenting of differential device-activity in 
dissimilar physiological environments, under direction of 
an external operator / physician
2-6
. 
Several nano sized pharmaceuticals were designed for oral 
delivery of nanotherapeuticmacromolecules but polymeric 
nanocarriers gaining popularity 
7
. They allows paracellular 
and transcellulartranscytosis of macromolecules and site 
specific delivery or targeting, and provide desirable 
biopharmaceutical and pharmacokinetic profile
8-11
. Their 
consensus on increasing efficacy, specificity, tolerability 
and therapeutic index and prognostic on minimising 
toxicities are available 
3, 4, 12-17
. 
Polymeric nanocarriers with diverse functionality were 
designed using several materials and following various 
process or technique. They be either a vesicular system 
(i.e., nanovesicles, encapsulates drug in a cavity of 
polymeric membrane) or a matrix system (i.e., 
nanoparticles (NPs), in which drug is physically and 
uniformly dispersed)
7, 12, 18, 19
. All of these systems have 
limitations and superiority over others. Choice of system 
afoot on desired physicochemical properties and targeted 
therapeutic objective 
3, 6, 7
.Biodegradable polymers of 
natural or synthetic origin used to wider extentwhile non-
biodegradable polymers are in rare use
1, 20
.Table 1 depicts 
glimpse on IUPAC name and structure of polymers used 
for developing nanocarriers, while Table 2 presents 
glimpse on specialism of nanocarriers. 
Adsorbing or grafting of molecules on surface of 
nanocarriers modifies its surface property that in turn 
modifies interaction with intestinal mucosa. Ligand 
molecule like antibodies, glycoproteins or peptides confers 
targeting 
9, 22-25
while that of hydrophilic one,polyethylene 
glycol (PEG), improves transcytosis
21
.Adsorbing or 
coating of them with mucoadhesives (viz. chitosan) 
imparts mucoadhesive property 
1, 5
. 
Present workinsights design andmanufacturing of 
NBODSMand underlinebalancing their physicochemical 
properties. Presented information has applicability in 
product evolution and will be a helping hand for 
developers, while designing them with excellent feature.
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Table 1: Depicts IUPAC name and structure of polymers used for developing nanocarriers 
POLYMER IUPAC NAME STRUCTURE 
Polyethylenimine Poly(iminoethylene) 
 
Poly(ε-caprolactone) (1,7)-polyoxepan-2-one 
 
Poly(glycolide) Poly[oxy(1-oxo-1,2-ethanediyl)] 
 
Poly(lactide) Poly[3, 6-dimethyl-1, 4-dione] 
 
Poly(lactide-co-glycolide) ---- 
 
Poly(cyanoacrylates) ---- 
 
Pluronic block 
copolymers 
---- 
 
Lecithin 
1,2-diacyl-sn-glycero-3-
phosphatidylcholine 
 
Tween Polyoxyethylenesorbitanmonooleate 
 
Span Sorbitan mono-oleate 
 
Cetylpalmitate Hexadecylhexadecanoate 
 
Sodium glycocholate 
 
Sodium 2-[4-(3,7,12-trihydroxy-10,13-
dimethyl-
2,3,4,5,6,7,8,9,11,12,14,15,16,17-
tetradecahydro-1H-
cyclopenta[a]phenanthren-17-
yl)pentanoylamino]acetate  
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NANOPARTICLES 
Physicochemical properties of NPs modulated with change 
in polymers and processing conditions. Modulation in 
hydrophobicity or surface charges, extent of drug loading, 
drug release profile, and biological behaviour make them 
versatility thereby amenable in orally delivering wide 
variety of drug with or without target specificity 
5, 16, 26
. 
Diverse methods followed for preparing them, depending 
on nature of polymer and drug. Use of process involving 
electrostatic interaction wise option, employ 
polyelectrolyte complexes and eliminates application of 
detrimental or aggressive in-process conditions 
27, 28
. While 
method requiring heat, organic solvent, sonication or 
vigorous agitation is unsuitable for biopharmaceuticals 
1, 
20
. 
 
Table 2: Nanocarriers exploited for developing oral delivery system of macromolecules 
Type of 
Nanocarriers 
Composition Size Range Specialism 
Nanoparticles Natural or synthetic, biodegradable or non-biodegradable 
polymers 
1-100 nm High kinetic stability, 
static structure 
Liposomes Natural or synthetic phospholipids 20 nm-10 µm Have dynamic 
structure and are 
biocompatible, safe, 
and well-tolerated. 
Solid-lipid 
nanoparticles 
High melting point natural or synthetic fats 50-1000 nm 
Micelles Ionic or non-ionic surfactants 2-20 nm 
Lipospheres High melting lipid,  phospholipids 0.2-100 mm 
Submicron lipid 
emulsions 
Lipids, hydrophilic liquid, surfactants 1-100 nm 
 
Natural, biocompatible polymers are alginate, agar, 
chitosan and its derivatives, dextran, gelatine, and so on. 
Synthetic, biocompatible and/or biodegradable are 
poly(cyanoacrylates) (PCA), poly(glycolide) (PGA), 
poly(lactide) (PLA), poly(lactide-co-glycolide) (PLGA), 
polyethylenimine or poly(ε-caprolactone) (PCL) 4-7, 20, 29, 
30
.Chitosan and its derivatives used popularly linked with 
biocompatible, non-toxic, mucoadhesive, targeting, and 
tight junctions (TJs) opening property
29-33
. Its limited 
solubility at pH > 6.5 being overcome by introducing alkyl 
groups to amine groups
34
. Polyelectrolyte complexes of 
200-400 nm size formed with these
27
. PLA, PLGA, PCL 
biodegrade through hydrolysis while PCA with esterase. 
PCL degrade slowly than PLGA, thus suitable for 
extending delivery
20, 35
. Chitosan used to greater extent 
while dextran, gelatine and alginate used to lesser extent 
1
. 
NANOVESICLES 
Surfactants and amphiphilic polymers / copolymers form 
colloidal dispersions of molecular aggregates or vesicles 
13, 
19, 36
. Lipid-based vesicles are solid-lipid nanocarriers 
(SLN), micelles, lipid microspheres (lipospheres) and 
liposomes (LIP) while surfactant based is niosomes
13, 14, 19, 
37, 38
. In contrast to NPs, which display a static and stable 
structure, they form a dynamic structure.  These can carry 
drug in core or on corona and can solubilise poorly soluble 
drugs and partly protect drug from aqueous environment, 
thus preferred for poorly soluble drugs
15, 18, 19
.SLN and 
niosomes are more stable and advantageous comparing 
LIP, can incorporate hydrophilic and/or hydrophobic drug. 
They protect incorporated drug from degradation; are 
biocompatible, safe, and well-tolerated; offer possibility 
for controlled release and drug targeting; and so on 
14, 15, 18, 
38
. SLN exhibit beneficial solid state behaviour 
(crystallinity, polymorphism and thermal behaviour) as 
consequences of non-spherical particle shape, usually. 
Crystalline natured lipid core of which contribute 
additional beneficent features, including altering 
pharmacokinetics profiles, comparing others
12, 37
. 
Copolymer of PLA-PEG, PCL-PEG, or low molecular 
weight polyester-PEG is cheaper and safe but their use 
limited by involvement of sophisticated technology and 
machine, and organic solvents. Lecithin, tween 80, 
poloxamer 188, span 85, cetylpalmitate, and sodium 
glycocholate are safe 
38
.Amphiphilic copolymers provide 
enhanced kinetic and thermodynamic stability comparing 
surfactants
14, 15, 18
.Copolymer of pluronic-polyacrylic acid 
and poloxamer results pH-sensitive micelles
39, 40
. 
Derivatives of PEGylated α-tocopherol and tocopherol 
polyethylene glycol succinate (TPGS), is biocompatible 
and suitable for delivering both soluble and poorly water 
soluble drugs
14, 15, 19, 38
.Poloxamer solubilise drugs and 
enhance drug transport across the intestinal barriers 
11, 41
. 
SLN formulated by solvent evaporation method or melt 
dispersion method but latter is advantageous as eliminates 
use of organic solvents 
42-44
.LIP, lipospheres and niosomes 
are formed either by simple direct dissolution in water or 
by dissolving drug and polymer in organic solvents before 
solvent evaporation or dialysis 
19, 36, 45, 46
. 
The polymers or copolymers use for micelles should (i) 
spontaneously self-assemble in water, (ii) enhance drug 
solubility by several fold (iii) provide high loading 
efficiency (iv) remain stable in the gastrointestinal (GI) 
tract, (v) be biocompatible and non toxic and (vi) easy to 
synthesise in commercial scale (vii) cheap and easily 
assessable. 
STABILITY OF NANOCARRIERS IN GI TRACT 
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After oral administration, nanocarriers degrade with 
variation of pH levels and presence of enzymes or bile 
salts. Their composition strongly influences stability in GI 
tract. Nanocarriers prepared with insoluble polymers 
neither immediately degrades nor rapidly releases drug. 
While that with water-soluble polymers, forming 
polyelectrolyte one, are more likely to destabilise by pH or 
ionic strength. Kinetic stability of NPs is better than 
nanovesicles
7, 13
. 
BIODISTRIBUTION OF NANOCARRIERS 
ATP-binding cassette (ABC) transporters (like P-
glycoprotein (P-gp) and multi-drug resistance-associated 
proteins expressed by intestinal epithelial membrane) and 
various solute transporters facilitate absorption of 
nanocarriers and or drugs. The ABC transporters are ATP 
dependent thus limits absorption in a dose-dependent, 
inhibitable and saturable manner and can pump against 
steep of concentration
41, 47-50
. 
Upon crossing mucus the nanocarriers are traversing 
intestinal epithelium via paracellular pathway and/or 
transcytosis. Receptor-mediated transcytosis 
(internalization through endocytic pathways) is specific to 
intracellular locations and processes and mediated by 
enterocytes or M cells
50
. Endocytosis mechanism involves 
phagocytosis and pinocytosis. Phagocytosis is restricted to 
M cells and phagocytic immune cells
47, 51
. Pinocytosis 
occurs by macropinocytosis (a transient process) and 
micropinocytosis (a constitutive pathway) 
5, 41
. 
Micropinocytosis involves clathrin-mediated endocytosis 
(ClME), caveolae-mediated endocytosis (CaME) and 
clathrin- and caveolae-independent endocytosis. ClME 
involves either specific receptor–ligand interaction or non-
specific endocytosis. Macropinocytosis and ClME 
involves fusion with endolysosomes whereas CaME 
involve direct exocytosis by escaping endolysosomes. 
CaME involves formation of flask-shaped invaginations, a 
static structures with a size of 50 to 100 nm, of the plasma 
membrane in cholesterol and sphingo lipid-rich 
microdomains
47, 50, 51
. 
After absorption, drug and/or drug loaded nanocarriers can 
be included in cytoplasmic vesicles or diffuse in cytoplasm 
and be discharged in serosal spaces for gaining access to 
mesentheric lymph or blood
5, 26,41, 48
.The size, composition, 
surface characteristics and architecture of them along with 
physicochemical properties of polymer (viz. molecular 
weight, conformation, hydrophobicity, and so on) will 
monitor their absorption 
9, 10, 47
. Water-insoluble polymers 
forms stable nanocarriers and are more likely absorbed as 
particles 
5
. Polymers forming less stable particles, 
polyelectrolyte complexes, vesicles or micelles will partly 
get dissociate and will not completely get absorbed as 
particle 
10, 14, 15, 38
.Nanocarriers taken up by absorptive 
enterocytes mainly delivered in blood. While those taken 
up by M cells will transcytosis close to immune cells and 
are likely be delivered to the gut-associated lymphoid 
tissue and lymphoid cells 
5, 9, 10
. Drugs encapsulated in NPs 
are not likely to be substrate of efflux pump while 
hydrophobic drugs forming core of micelles are more 
likely to be transported by efflux pumps 
5, 10, 11
.Delivery 
mechanism of macromolecule through oral route is 
presented with Figure-1. 
 
 
BIOAVAILABILITY IMPROVEMENT 
TECHNIQUES 
In paracellular route junction-proteins present at tight or 
adherens junction restrains passage of macromolecules or 
aggregates with size more than one nm. Consensus on 
nanocarriers is generally they do not transverse intestinal 
barrier by paracellular route
22, 26, 48
. While in transcellular 
route major limiting factor is intestinal mucosa which 
requires redresses for improving bioavailability of orally 
delivered macromolecules 
5, 8, 16, 22, 41, 47, 50, 52
. 
Improvement in delivery of drug, by paracellular way, can 
be achievable by grafting modulators of junctional proteins 
on the surface of nanocarriers
5, 22
. These modulators act 
directly or indirectly on TJ components, proteins or surface 
receptor resulting reversible opening of membranous 
barriers 
32, 33
. Some modulators disrupt the TJs via 
activation of protein kinase C and the adherens junctions 
by chelating calcium 
22, 47, 50
. 
Transcellular translocation of nanocarriers seems 
influencing by several physicochemical parameters 
including surface hydrophobicity, polymer nature and 
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particle size. These factors influence their fate within 
enterocytes or M cells while efflux pumps may strongly 
reduce extent of net drug uptake 
8, 16,41, 47, 50
. 
Bioavailability or performance of nanocarriers ought to be 
improving through protecting drug from detrimental GI 
tract environment, prolonging their GI-residence time by 
mucoadhesion, their endocytosis, and permeabilising effect 
of polymer 
1, 5, 8, 39, 47
. 
ENDOCYTOSIS  
Internalization of nanocarriers through endocytosis 
pathway depends on physicochemical characteristics and 
size of the particle and the cell type. Their transport can be 
enhanced by specifically targeting receptors (mediating 
endocytosis) through grafting or coating them with ligand, 
having affinity for receptors 
8, 22, 41, 47, 49, 50
.Several non-
exhaustive receptors are there whose targeting can be done 
to increase their transport mediated by intestinal cells, 
globet cells or M cells 
9, 24, 47, 49, 51, 53, 54
.Pattern recognition 
receptors (PRRs) such as toll-like receptor-4,platelet-
activating factor receptor and α5β1 integrinpresent on the 
surface of M cells considered as important in antigen 
transcytosis
55
. A few specific ligands of human M cells 
have been identified 
3, 9, 23
. Grafting of these M cell homing 
peptides (CKSTHPLSC (CKS9), CSKSSDYQC (CSC)) 
results in targeting of M cells and enhances transport 
23, 56, 
57
. Nanocarriers mimicking structure of pathogen or having 
affinity for M cells is suitable for oral immunisation 
55
. 
Integrins can be targeted with Arg-Gly-Asp (RGD) and 
aspartic-acid-based ligands. Among these RGD peptides 
cyclic peptides c(RGDfK) and c(RGDyK), RGD4C, and 
RGD10 showed high binding affinity and selectivity for 
integrin
54
. 
TARGETING  
Many emerging nanocarriers are essentially delivery 
devices strongly emphasising on control of therapeutic 
action in time and space
1
.Targeted delivery devices 
depending on biologic affinity interactions (using vascular 
address system) and physical/chemical properties 
(enhanced permeability and retention effect), and pro-drug 
strategies (devices that are active only at preselected sites 
of disease) have emerged recent years 
3, 6, 9, 16
. Other 
related modalities are controlling the assembly or activity 
of devices at particular sites or at particular times in 
response to a signal provided by an external operator. Such 
signals are physical (a magnetic field) or biochemical (an 
enzyme transforming therapeutic to an active form) in 
nature
32, 49
. Up-regulating expression of some receptors 
using an appropriate stimulant is another strategy of 
targeting. Stimulation of these receptors with ligands, 
lipopolysaccharide or cytokines increases particle uptake 
by human follicle-associated epithelium cells 
5, 8, 9, 56, 57
.  
Some lectins can result targeting of adhesion molecules 
present on enterocytes and M cell membranes. Grafting of 
ligand is particularly attractive for oral vaccine delivery 
9, 
23, 57
. Adhesive factors (flagellin and invasins) derived 
from microorganisms, vitamins, and carbohydrates are 
used as ligands 
1, 5, 58, 59, 60
.  
Conjugating lectins to nanocarriers increases transport 
across the intestinal mucosa while grafting them with 
vitamin B12allows targeting to intrinsic factor specific 
receptor
10, 50, 60, 61
. Targeting of NPs and internalisation of 
micelles takes place via ClME. Endocytic translocation of 
small particles (with size 50-100 nm) mediated by 
enterocytes whilst larger particles mediated by M cells 
10, 
41, 47, 50, 51
.Chitosan and PLGA nanocarriers enhance 
transport via ClME
31
. Nanocarriers coated or grafted with 
ligands like folic acid, albumin and cholesterol, gets 
internalized by CaME
51
. Targeting of globet cell 
53
, peyer’s 
patches (PPs)
45, 56
, dendritic cells (DCs) of PPs 
62
 done by 
grafting ligands, having homing property or affinity 
forthem. Pluronic 85 unimers enter epithelial cells through 
caveolae-dependent and caveolae-independent pathways 
63
. Thiamine-coated NPs captured by PPs 
58, 56
.  
MUCOADHESION 
Prolongation in GI-residence time of nanocarriers will 
improve efficiency in transversing intestinal epithelium, 
thereby improving bioavailability
26, 39, 58
. This ought to get 
improved by decreasing their size below 200 nm, which in 
turn will diffuse through mucus and circumvent 
elimination by mucilliary clearance. Mucoadhesion 
translates to cumulative protein release and absorption
39, 59, 
64
. 
DISCUSSION AND STRATEGY FOR 
DEVELOPMENT 
Nowadays NBODSM considered as promising alternative 
to parenteral one. pH sensitive, untargeted, or targeted 
(with or without grafting of ligand) NBODSM had been 
exploited in most cases 
1, 5, 16, 30, 65
. Future of their 
marketing remains uncertain due to following facts. 
(i) High cost of synthesising polymer, manufacturing 
nanocarriers and scaling-up, 
(ii) Improvement of bioavailability to stable and 
efficient therapeutic level,  
(iii) High inter- and intra-individual variations in 
pharmacokinetics of macromolecules, and  
(iv) Optimizing polymeric composition of them for 
specific macromolecules. 
Selection of nanocarrier remains controversial for 
delivering macromolecules. Amenability of NPs for 
modulation in physicochemical and biological behaviour 
makes them versatile, thus suitable for delivering wide 
variety of drug with or without target specificity
5
. Micelles 
considered viable approach for delivering poorly soluble 
macromolecules comparing cyclodextrins based solid 
dispersions or lipid-based systems
13, 19, 36, 38
. pH-sensitive 
micelles minimises initial burst release of macromolecules 
in stomach but releases them at pH 5, in a molecularly 
dispersed form
40
. LIP and lipospheres have lower toxicity 
and higher tolerability, and suitable for poorly soluble 
macromolecules 
45, 46
.SLN, comprises physiological and 
well-tolerated lipids, offer controlled release and targeting, 
provide protection against degradation, and is 
advantageous over other colloidal carriers 
12, 42, 44, 66, 67
. 
Size of nanocarriers should be essentially within 10-200 
nm, to promote diffusion in mucus and uptake by intestinal 
cells, and to decrease uptake by reticulo-endothelial 
system (RES) 
16
. Surface modification of them with PEG 
will prevent their uptake by RES and prolong circulation 
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half-life
21, 25
. Imparting mucoadhesion property will 
prolong their residence time without impeding diffusion in 
mucus 
39, 58, 59
.Their surface charge has to be positive 
favouring interaction with mucus and cell membrane but 
be neutral to decrease RES clearance
26, 39, 64
. 
The mechanisms of drug absorption from micelles differ 
from NPs uptake. Nanocarriers should be stable in GI tract 
while releasing drug at desired site with predetermined 
rate. They may have targeting potentiality for M cells or 
immunocompetent cells of GI tract
9, 38, 47, 50
.  
Chitosan have ability to cause reversible opening of TJs 
and have mucoadhesive property 
29, 32, 33, 68
.Improvement in 
paracellular permeability did not increases permeability of 
endotoxins and lipopolysaccharide thus is safe
69
. 
Polyelectrolyte complexation of drug with chitosan 
prevents enzymatic degradation in GI environment
28
. 
Hydrogel system of alginate, dextran sulphate and 
poloxamer 188 consisting multilayered NPs of chitosan 
improves entrapment and gastric retention. Poloxamers 
improves solubility and transport of drug 
8, 41, 48
. 
Decreasing concentration of Ca
2+
 and increasing 
concentration of poloxamer and albumin results smaller 
NPs. Reduction in albumin content improves entrapment 
and gastric retention
10, 11
. 
Loss in mucoadhesive and TJopening properties of 
chitosan at pH 7.4 is improved by derivatisation
29, 33, 34
. N-
trimethylated chitosan (NTC), thiolated chitosan (TC)
68
, 
N-(2-hydroxyl) propyl-3- trimethyl ammonium chitosan 
(NTAC)
70
, are important derivatives
29
. These categorised 
as pH-sensitive polymers used for improving 
bioavailability alone or in combination with other polymer 
4, 71
. PEGylatedchitosan have enhanced permeability and 
lower toxicity 
25
. Gama-polyglutamic acid (γPGA)-NTC 
based NPs allow absorption of macromolecules throughout 
the intestinal tract
71, 72
. 
NTC based NPs involve active transport and electrostatic 
interaction, which upon conjugation with ligand CKS9, 
CSC enhances absorption, further, via clathrin- and 
caveolae- mediated endocytosis 
23, 53, 56, 57
.From pH-
responsive NPs macromolecules gets absorbed into 
systemic circulation while carrier retained mainly in oral 
tract 
65, 73
. Some pH-responsive nanocarriers are 
biodegradable 
40
.TC improves mucoadhesion and 
absorption eliminating toxicity and biocompatibility issue 
68
. NTAC exhibit higher cationic charge density, increased 
mucoadhesion, TJ opening ability and were non-cytotoxic 
70
. 
NPs of chitosan-γPGA increase their absorption in 
intestine and sustain release. Their conjugation with CSC 
results targeting of goblet cells,but with 
diethylenetriaminepentaaceticacid disruptsTJs
71
. Blending 
chitosan and γPGA with tripolyphosphate and MgSO4 
result multi-ion-crosslinked NPs, possessing stability over 
broader pH ranges and improved transporting capability, 
and more compact one
8, 29
. 
Acrylic-based polymers and copolymers like 
poly(isobutylcyanoacrylate) (PIBCA), poly(acrylic acid) 
(PAA), poly(alkylcyanoacrylate), PEG grafted methacrylic 
acid (MAA) or acrylic acid used to get pH sensitive NPs. 
Copolymerising MAA with PEG dimethacrylate (PG-
DMAA) having molecular weights of 400-4000 g/mol 
results hydrophilic and pH-sensitive poly(PG-DMAA-
MAA) NPs 
5, 7, 25, 30
.Modification of dextran based NPs 
through conjugation of its surface with vitamin B12 results 
targeting with better transport and higher 
bioavailability
60
.Thiolatedpoly(acrylic acid) or it’s blend 
with chitosan  improves mucoadhesive properties of NPs
68, 
74
. 
PLGA NPs gets distributed in liver, spleen, lungs, brain 
and kidneys, while majority were located in liver but these 
upon PEG-grafting rapidly taken up by peritoneal 
macrophages 
31
. PLGA or its blend with β-cyclodextrin 
(PLGA-βCD), hydroxypropyl methylcellulose phthalate 
(PLGA-HP55) and Eudragit® RS (PLGA-ERS) are also 
exploited 
75
. PLGA-βCD, PLGA-HP55 and star-branched 
form of PLGA exhibit burst release effect. While PLGA-
ERS based NPs remains attached to intestinal epithelium 
and able to open TJs
75
. γPGAgraftedmesoporoussilicaNPs 
are pH-sensitive and possess much higher release rate at 
pH 5.5 comparing pH 7.4 
72
.PLGA based NPs upon 
coating with chitosan exhibit improved mucoadhesion
59
. 
Co-encapsulating antacids (viz. magnesium hydroxide, 
magnesium carbonate or zinc carbonate) in PLGA NPs 
preserve the structure of macromolecules and protect them 
from GI tract degradation 
76
. PLGA-based NPs targeting M 
cells might be more efficient for vaccine delivery that 
sustain release and deliver antigen directly to the immune 
cells and might achieve and have intrinsic adjuvanteffect 
on DCs 
31, 57, 77
.PCL-ERS, and poly(allylamine) are 
alternatives for getting mucoadhesive NPs. 
Dipalmitoyl-phosphatidylcholine (DPPC), egg, 
phosphatidylcholine, or phosphatidylinositol-cholesterol 
based LIP are used while DPPC offers protection of drug 
against degradation in GI tract and their entry in 
bloodstream, intact 
45, 46
. Surface conjugation or coatings 
of LIP with mucin, PEG, wheat germ agglutinin (WGA), 
tomato lectin (TL) and Ulexeuropaeus agglutinin 1 (UA1) 
results targeting. Mucin-LIP and PEG-LIP results 
sustained release and provides protection against bile salts 
1, 45, 46
. LIP-WGA is taken up by endocytosis, LIP-TL 
exhibits resistance to enzymatic action in the intestine and 
mucoadhesion, LIP-UA1 have targeting specificity to M 
cells of PPs 
9, 45, 56, 57
. Co-encapsulation of permeation 
enhancers (e.g. sodium taurocholate, dimethyl 
palmitoylammoniopropanesulfonate) enhances 
bioavailability and paracellular translocation, through 
disrupting TJ 
78
. 
Poly(allylamine) are amphiphilic and protects 
macromolecules from degradation by pepsin, trypsin and 
chymotrypsin along with improvement of transcellular and 
paracellular transport while latter being via reversible 
disruption of TJs 
28, 79
. PLA-Pluronic block copolymer 
based vesicles have ability to pass through cell membranes 
and attracted to small intestine
63
. Copolymer of pluronic-
PAA and poloxamer minimise initial burst release of drug, 
in the acidic stomach, but releases drug, in a molecularly 
dispersed form, at pH five. Targeting and mucoadhesion 
property of these synergises efficiency and efficacy 
39
. 
SLN ofcetylpalmitate sustain release while that of WGA-
N-glutarylphosphatidylethanolamine exhibits protection 
against enzymatic degradation 
11, 12, 43, 67, 80
.Micelles of 
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monomethyl PEG750-poly(caprolactone-co-
trimethylcarbonate), copolymer, confers 1 to 3 fold 
increase in solubility of poorly soluble drugs and 
bioavailability 
14, 18
. 
To avert drug release in GI tract, concentration of micelle 
to be above critical micelle concentration (CMC) and it 
shall expose to an ionic strength below their flocculation 
point 
27, 81
.The inhibition of P-gp by pluronics is highest 
just below CMCwhereas that of PCL-PEG is above CMC 
14, 18
. Micelles of poorly soluble drugs could be passively 
target by enhanced permeabilisation-retention effect 
14
. 
Poly-ion complex micelle enhances transport across 
intestinal epithelial barrier 
27, 28
. 
Pluronics, poloxamers, TPGS and PCL-PEG inhibit P-gp 
and enhance net drug transport through intestinal barrier 
14, 
18, 41, 63
.Some NPs enhances transcytosis through 
proteaseinhibition
82
. Multilayered NPs of alginate co-
localises in the small intestinal mucosa. Amine-modified 
graft polyesters-chitosan NPs or thiolatedtrimethylchitosan 
NPs conserving degradation of macromolecules and 
facilitate their uptake, while latter had intrinsic 
adjuvanteffect on DCs 
48, 77
. 
Lipid-based systems (lipospheres, micelles, and LIP), 
prepared with several lipids including orexcluding 
emulsifying agents, well tolerated in living systems did not 
exhibit any cytotoxic effects, up to total of 2.5% lipid 
content. LIPisadvantageous in terms of 
amphiphiliccharacter, biocompatibility, and ease of surface 
modification.SLNis innovative system having 
expectationfor more contributions, particularly,poor 
aqueous soluble macromolecules. Considering tolerability, 
surfactant of GRAS status used with preference, 
comparing lipids. Acylglycerols composed of fatty acids 
and lecithins mostly accepted as safe 
19, 38
. 
Surface charges or chemistry of nanocarriers seem to 
monitor their fate. Negatively charged one display higher 
transport rates referring near neutral, or positively 
charged
5, 64
. Fast-diffusing nanocarriers are achievable by 
coating their surface with PEG. This surface engineering 
modulates their mucoadhesive properties. Dense coating 
effectively minimises adhesive interactions of them with 
mucins, allowing penetration 
21
.GI-residence time can be 
improved with cationic polymers or coating them with 
cationic groups or with thiol groups (binds to mucin)
21, 35.
 
However, a balance between mucoadhesion and mucus 
penetration is important 
5
. 
Nanocarriers must be small enough to avoid significant 
steric inhibition by the fibre mesh and should avoid 
adhesion to mucin fibres; and to allow diffusion and 
uptake, but large enough to carry a favourable amount of 
macromolecules 
48
. They being stable, non-toxic, 
bioabsorbable, non-thrombogenic, non-immunogenic, non-
inflammatory, avoid uptake by RES and have versatile 
applicability 
1, 17, 20
. Cytotoxicity of nanovesicles is an 
essential product parameter of in vivo tolerance evaluation 
in humans and/or animals
17, 19, 38
.Their stability assessed 
involving approved method and accordingly shelf-life be 
assigned 
39
. 
Targeting of nanocarriers to globet cell 
53, 54
PPs 
9, 45, 56
DCs 
of PPs
57, 62
achieved with grafting of ligands. Optimisation 
of ligand density on their surface must allow tissue 
penetration and cellular uptake resulting in optimal 
therapeutic efficacy. Redressing issue of variation in M 
cells populations and receptors needed; those vary with 
species, anatomical location, age, sex and exogenous 
factors
1, 9, 10
. 
In vitro models used for understanding fate of nanocarriers 
within intestinal epithelium is critical for their 
development. Combining both quantitative analysis 
method studying their transport and confocal microscopy, 
locating them, improve efficiency of study 
39, 83
. Cellular 
tracking of them can be done with quantum dots technique 
that improves their visualization and dynamic 
colocalization microscopy 
61, 83
. Quantitative and 
qualitative information such as diffusivity, viscoelasticity, 
pore size, velocity, directionality and transport mode of 
drug vectors can be determined from particle trajectories 
that reflect transport in mucus. 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide assays provide 
cytotoxic report of the nanocarriers
70
. Association of 
nanocarriers with DCs and their effect on their maturation 
determined flow-cytometrically
77
.  
Novel NBODSM can be developed through 
1
. 
(i) Development of biocompatible polymers with tailored 
attributes for orally administered nanocarriers,  
(ii) Understanding the mechanisms of their cellular uptake,  
(iii) Devising novel techniques for studying their fate 
including its components, and  
(iv) Identifying ligands for their targeted delivery.  
CONCLUSION  
NBODSM will be a promising platform for orally 
delivering macromolecules. In vivo experimental results of 
animal models need to be interpreted and correlated with 
care, associated with existence of differences in anatomy 
and physiology of laboratory animals and humans. In order 
have successful NBODSM bioavailability of them to reach 
therapeutic level, with minimal inter and intra individual 
variation and toxicity had to be considered. Greater 
stability along with a financially feasible manufacturing 
process for mass production is prerequisite. Future will 
evidence utility of NBODSM in devising projected benefit 
in a cost-effective and sustainable way. Step to set up to 
arouse professional in delivering worthwhile effects to 
society.
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